Values as of: 2024-11-17
ETF | Health |
Last Closing
USD 86.59Change
0.00 (0.00)%Market Cap
USD 0.67BVolume
0.70MAnalyst Target
N/AVerdict
Verdict
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Company Website : http://www.vaneck.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| IBB | iShares Biotechnology ETF |
N/A |
USD 6.55B |
| BBH | VanEck Biotech ETF |
N/A |
USD 0.43B |
| PSCH | Invesco S&P SmallCap Health Ca.. |
N/A |
USD 0.18B |
| PTH | Invesco DWA Healthcare Momentu.. |
N/A |
USD 0.14B |
| GNOM | Global X Genomics & Biotechnol.. |
N/A |
USD 0.08B |
| FTXH | First Trust Nasdaq Pharmaceuti.. |
N/A |
USD 0.02B |
| CNCR | Loncar Cancer Immunotherapy ET.. |
N/A |
USD 0.01B |
N/A
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 6.42% | 88% | B+ | 61% | D- | ||
| Dividend Return | 1.60% | 100% | F | 32% | F | ||
| Total Return | 8.01% | 88% | B+ | 60% | D- | ||
| Trailing 12 Months | |||||||
| Capital Gain | 11.95% | 50% | F | 59% | D- | ||
| Dividend Return | 2.07% | 100% | F | 30% | F | ||
| Total Return | 14.02% | 63% | D | 58% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 40.73% | 88% | B+ | 69% | C- | ||
| Dividend Return | 10.93% | 100% | F | 37% | F | ||
| Total Return | 51.66% | 100% | F | 70% | C- | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 7.90% | 100% | F | 59% | D- | ||
| Dividend Return | 9.66% | 100% | F | 59% | D- | ||
| Total Return | 1.76% | 88% | B+ | 46% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 12.65% | 88% | B+ | 86% | B+ | ||
| Risk Adjusted Return | 76.37% | 100% | F | 90% | A- | ||
| Market Capitalization | 0.67B | 88% | B+ | 66% | D+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
The stock is trading high compared to its peers median on a price to book value basis.
